What percentage of pediatric Mycoplasma pneumoniae infections are resistant to macrolide antibiotics?
Macrolide antibiotics (like azithromycin) are the standard treatment for Mycoplasma pneumoniae infections in children. However, resistance to these drugs has become common in many parts of the world, especially Asia. The exact percentage of resistant infections depends on the location and the year the study was done. In some recent studies from China and Japan, resistance rates have been very high, over 80%.
What the research says
A 2024 study in Anhui, China, found that 94.4% of 71 pediatric Mycoplasma pneumoniae isolates were macrolide-resistant 4. This is one of the highest rates reported. In Japan, a study from 2012-2013 found that 89% of 27 culture-positive children had resistant strains 9. In Taiwan, resistance increased from 22% in 2015 to 70% in 2019 8. A Chinese study from 2018 reported that 81 out of 136 children (about 60%) had macrolide-resistant Mycoplasma pneumoniae pneumonia 10. These studies show that resistance is a major problem, especially in East Asia. The most common genetic change causing resistance is the A2063G mutation in the 23S rRNA gene 49.
What to ask your doctor
- What is the local resistance rate for macrolides in Mycoplasma pneumoniae?
- If my child has Mycoplasma, should we test for macrolide resistance before starting treatment?
- What alternative antibiotics (like tetracyclines or fluoroquinolones) are available if macrolides don't work?
- What signs should I watch for that might indicate the infection is not responding to treatment?
- Are there any special considerations for treating macrolide-resistant Mycoplasma in children?
This question is drawn from common patient questions about Infectious Disease and answered using cited medical research. We do not provide individualized advice.